A switch from current HMG CoA reductase inhibitor [statin] therapy to either cerivastatin 0.4 or 0.8 mg/day or simvastatin 80 mg/day

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1307, 2001-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMG CoA reductase inhibitor [statin] therapy should be considered for older patients

By  

Inpharma, Vol. 1, Iss. 1237, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Cerivastatin: the low-dose HMG-COA reductase inhibitor

By Tikkanen M.J.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. : 161-166

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of 24 Weeks of Therapy with Bendroflumethiazide 1.25 mg/day or 2.5 mg/day and Potassium Chloride Compared with Enalapril 10 mg/day and Amlodipine 5 mg/day in Patients with Mild to Moderate Primary Hypertension: A Multicentre, Randomised, Open Study

By Rasmussen S.  

Clinical Drug Investigation, Vol. 26, Iss. 2, 2006-01 ,pp. : 91-101

Adis International

Access to resources Recommend Favorite

Comparison of Efficacy of Low- (80 mg/day) and High- (160-320 mg/day) Dose Valsartan in the Prevention of In-Stent Restenosis after Implantation of Bare-Metal Stents in Type B2/C Coronary Artery Lesions

By Peters Stefan  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 2, 2008-01 ,pp. : 83-87

Adis International

Access to resources Recommend Favorite

Efficacy of Tamsulosin 0.4 mg/day in Relieving Double-J Stent-related Symptoms: a Randomized Controlled Study

By Navanimitkul N   Lojanapiwat B  

The Journal of International Medical Research, Vol. 38, Iss. 4, 2010-07 ,pp. : 1436-1441

Field House Publishing

Access to resources Recommend Favorite